The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153.
Costantine Albany
No relevant relationships to disclose
Nasser H. Hanna
No relevant relationships to disclose
Joel Picus
No relevant relationships to disclose
Ralph J. Hauke
No relevant relationships to disclose
Christopher A. Fausel
Employment or Leadership Position - Hoosier oncology grroup
Ziyue Liu
No relevant relationships to disclose
Mary J. Brames
No relevant relationships to disclose
Lawrence H. Einhorn
No relevant relationships to disclose